No registrations found.
ID
Source
Brief title
Health condition
chemotherapy induced nausea and vomiting, adherence to guidelines, efficacy antiemetics, quality of life.
chemotherapie geinduceerde misselijkheid en braken, opvolgen behandelrichtlijnen, effectiviteit anti-emetica, kwaliteit van leven
Sponsors and support
Ziekenhuisapotheek Medisch Centrum Alkmaar
Intervention
Outcome measures
Primary outcome
1. To make an inventory on the antiemetic policy in several peripheral hospitals;
2. To make an inventory on the effectiveness of these antiemetic policies.
Secondary outcome
1. What is the difference in antiemetic policies used in several peripheral hospitals?
2. Do these antiemetic policies correspond with evidence based guidelines?
3. Is aprepitant used in high emetogenic chemotherapy treatment or moderate emetogenic chemotherapy treatment?
4. What is the incidence of acute and delayed nausea and vomiting in chemotherapy treatment and does this correspond with literature?
5. Can differences in effectiveness be explained by differences in patient characteristics, chemotherapy and/or antiemetic policy?
Background summary
Nausea and vomiting are still two of the most serious side effects in chemotherapy treatment, even after the introduction of 5HT3 antagonists. The effectiveness of antiemetics used in the prevention of nausea and vomiting is not sufficient according to literature. Especially the prevention of delayed nausea and vomiting is difficult.
This study uses self reported sides effects including nausea and vomiting by means of a patient diary which also includes a quality of life assessment.
This outcomes research provides insight into the effectiveness of antiemetic policies in daily practice, in several peripheral hospitals.
Study objective
1. Adherence to guidelines/protocols is unsatisfactory;
2. No regimen is superior in the proportion of patients with minimal or no impact of emesis on daily living as measured using the Functional Living Index-Emesis questionnaire.
Study design
N/A
Intervention
This study uses self reported sides effects including nausea and vomiting by means of a patient diary which also includes a quality of life assessment.
P.O. Box 501
H.J. Doodeman
Alkmaar 1800 AM
The Netherlands
+31 72-5483591
h.j.doodeman@mca.nl
P.O. Box 501
H.J. Doodeman
Alkmaar 1800 AM
The Netherlands
+31 72-5483591
h.j.doodeman@mca.nl
Inclusion criteria
1. Chemotherapy naive patients receiving chemotherapy.
Exclusion criteria
1. Life expectancy less than three months;
2. Lack of basic proficiency in Dutch;
3. Age below 18;
4. Pregnancy;
5. Psychological illness.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL974 |
| NTR-old | NTR1001 |
| Other | : P05.0473L |
| ISRCTN | ISRCTN55375237 |